GT Biopharma, Inc. Announces Restatement of Q2 2025 Financial Results

Key Highlights

• Restatement of Financials: GT Biopharma, Inc. (Nasdaq: GTBP) has filed an amended Form 10-Q/A for the quarter ended June 30, 2025, restating its balance sheet, statement of operations, and statement of cash flows due to material errors in the original filing.
• Material Accounting Error: The company failed to classify “Greenshoe Rights” related to its Series L Convertible Preferred Stock (issued in May 2025) as a liability. These should have been marked-to-market at each reporting date per GAAP standards (ASC 480).
• Audit Committee Action: On March 1, 2026, GT Biopharma’s audit committee concluded that the previously reported Q2 2025 financials should not be relied upon, resulting in the restatement.
• Internal Controls: The company declared its disclosure controls and procedures as of June 30, 2025, were ineffective due to the identified errors.

Financial Statement Restatement – Details

Balance Sheet Adjustments

• Greenshoe Rights Liability: Newly recognized liability of \$28.7 million for Greenshoe Rights as of June 30, 2025.
• Dividend Payable: Dividends payable increased to \$85,000 as of June 30, 2025.
• Total Liabilities, Mezzanine Equity, and Stockholders’ Deficit: Total increased to \$7.12 million at quarter end, up from \$4.23 million at December 31, 2024.
• Stockholders’ Equity (Deficit): Deepened negative equity position, with a deficit of \$22.9 million, compared to \$1.44 million deficit at year-end 2024.
• Additional Paid-in Capital: Rose to \$700.4 million from \$693.6 million at year-end.
• Retained Earnings (Accumulated Deficit): Increased deficit to \$726.3 million, up from \$695.2 million previously.

Statement of Operations – Key Figures

• Net Loss: Net loss for the six months ended June 30, 2025, widened significantly to \$30.95 million, compared to \$5.98 million for the same period in 2024.
• Nonoperating Expense: A substantial nonoperating expense of \$27.5 million was recorded for the six months ended June 30, 2025, largely attributable to the Greenshoe Rights liability adjustment.
• Operating Loss: Operating loss for the period was \$3.45 million, an improvement from \$6.99 million in 2024.
• Net Loss Per Share: Net loss per share (basic and diluted) for the six months ended June 30, 2025, was \$12.12 compared to \$2.17 in the prior year.
• Dividends on Preferred Stock: \$85,000 declared for the period.

Cash Flow Statement

• Net Cash Provided by (Used in) Operating Activities: Not directly stated, but negative equity and increased liabilities suggest continued cash burn.

Corporate Information

• Shares Outstanding: As of August 8, 2025, GT Biopharma had 3,557,502 shares of common stock outstanding.
• Listing: Common stock trades on Nasdaq Capital Market under the symbol “GTBP”.
• Filer Status: GT Biopharma is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company or a shell company.

Shareholder and Price-Sensitive Considerations

• Restatement and Material Error: The restatement of financials, particularly the recognition of a \$28.7 million Greenshoe Rights liability, is a material event and may impact investor confidence, valuation, and compliance with Nasdaq listing requirements.
• Deepening Equity Deficit: The increase in negative shareholder equity and substantial net loss are likely to be perceived negatively by investors.
• Internal Controls Lapse: Company’s admission of ineffective disclosure controls may raise concerns about future reliability of its financial reporting and governance.
• Potential Impact on Share Price: The combination of these events—restatement, liability recognition, and internal control weaknesses—constitutes significant, price-sensitive information that could affect GTBP’s share value and trading activity.

Summary Table of Key Restated Figures

What Investors Should Watch Next

• Further scrutiny from regulators or Nasdaq is possible, given negative equity and material errors.
• Management’s response to internal control weaknesses and any additional changes to governance or financial reporting practices.
• Potential dilution or capital raising activities, given ongoing losses and negative equity.
• Market reaction to restated results and the significant liability recognition.

Disclaimer

This article is intended for informational purposes only and does not constitute investment advice. Investors are encouraged to perform their own due diligence and consult with financial advisors before making any investment decisions. All financial figures are based on unaudited, restated filings and may be subject to further revision. The information presented herein may be price-sensitive and could affect GT Biopharma’s share value. The author does not hold any position in GT Biopharma, Inc.

View GT Biopharma, Inc. Historical chart here